GSK and CureVac restructured their 2020 collaboration into a new licensing agreement worth up to $1.57 billion in July 2024.

GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's ...

GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK is targeting Moderna in a pair of lawsuits alleging the Massachusetts-ba | ...

GlaxoSmithKline has filed lawsuits against Moderna in the U.S., claiming infringement on its mRNA technology patents with ...

Pharmaceutical firm GlaxoSmithKline (GSK) announced Tuesday it received approval from the Food and Drug Administration (FDA) ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

GSK said its depemokimab respiratory drug met the main objectives in two late-stage clinical trials, showing efficacy for the treatment of chronic rhinosinusitis with nasal polyps.

These FTSE shares don’t have the highest yields. But Edward Sheldon believes they could deliver attractive returns in the years ahead. The post Here are the 2025 dividend forecasts for FTSE giants ...

SG Americas Securities LLC increased its position in GSK plc (NYSE:GSK – Free Report) by 167.3% in the third quarter, ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...